Prostate CancerPhase 2SChLAP/IDCNCT04176081
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
A Phase 2 study testing Darolutamide, Degarelix and Radiation Therapy in people with Prostate Cancer, run by University Health Network, Toronto at 1 site in Canada.
Trial summary
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and second leading cause of cancer-related death. Men with PCa have a wide range of possible outcomes if the cancer has not spread and is classified as Intermediate-Risk PCa (IR-PCa). Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- Darolutamide, Degarelix and Radiation Therapy
- Type of treatment
- Pill or oral medicine, Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 208 participants
- Where
- 1 siteCanada
- Study dates
- 2 Jul 2024to Dec 2028
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male ≥ 18 years of age;
- Pathologic (histologic) proven diagnosis of prostate adenocarcinoma within 180 days prior to consent;
- PSA measurement performed within 60 days prior to consent;
- IR-PCa as per National Comprehensive Cancer Network (NCCN) criteria (PSA >10 and < 20 ng/mL and/or Gleason score 7 and/or T-category T2b-T2c clinical or ultrasound);
- UIR-PCa, at least one of the following:
- 2 or 3 NCCN IR-PCa criteria;
Show all 12Show fewer
- Gleason score 4+3;
- >50% diagnostic cores involved by adenocarcinoma;
- Clinically negative (N0) stage, as defined by pelvic-CT or pelvic-MRI within 4 months prior to consent;
- No evidence of bone metastases (M0) assessed by a bone scan within 4 months prior to consent;
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
- Able and willing to provide signed informed consent as per International Conference on Harmonization - Good Clinical Practices Guidelines (ICH-GCP) and applicable regulations.
Who cannot join
- Received any form of hormonal therapy such as bilateral orchiectomy, LHRH agonist/antagonist (e.g. goserelin, leuprolide, degarelix, etc.), anti-androgens (e.g. flutamide, bicalutamide, etc.), 5α-reductase inhibitors (e.g. finasteride, dutasteride, etc.) and/or estrogens within 1 year of consent;
- Received prior cytotoxic therapy for prostate cancer (e.g. taxanes, mitoxantrone);
- Currently taking medications that might cause toxicity if combined with darolutamide (see section 4.6);
- Hemoglobin < 9.0 g/dL, independent of transfusion and/or growth factors, measured within 90 days prior to consent;
- Platelet count < 100,000 × 109/μL, independent of transfusion and/or growth factors, within 90 days prior to consent;
- Serum albumin < 3.0 g/dL within 90 days prior to consent;
Show all 20Show fewer
- Abnormal renal function, assessed within 90 days prior to consent:
- Creatinine > 2mg/dL;
- Glomerular filtration rate (GFR) ≤ 35 mL/min, estimated by Cockcroft-Gault formula or measured directly by 24 hour urine.
- Abnormal liver function assessed within 90 days prior to consent:
- Total bilirubin > 1.5 times the upper limit of normal range;
- Aminotransferases (ALT or AST) >1.5 times the upper limit of normal range;
- Currently on anticoagulant therapy for any indication (e.g. atrial fibrillation, valve replacement, pulmonary embolism, etc.);
- Any cardiac events (e.g. unstable angina, myocardial infarction and/or congestive heart failure;
- Does not agree to use highly effective method of birth control if he is having sex with a woman of childbearing potential or does not agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 4 weeks following the last dose of study drug;
- Known hypersensitivity (or known allergic reaction) to the study treatment(s) or any of its ingredients (as listed in Investigator's brochure);
- Planned initiation of alternative therapy for prostate cancer or investigational therapy;
- Participation in another interventional clinical trial during and / or within 3 months of consent for this study;
- Subject was previously randomized in this trial;
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Prospective, Randomized, Open-label, Multi-centre, Phase II Trial Evaluating IDC/SChLAP1 as a Biomarker for Prediction of Response to Intensified Combined Modality Treatment
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and second leading cause of cancer-related death. Men with PCa have a wide range of possible outcomes if the cancer has not spread and is classified as Intermediate-Risk PCa (IR-PCa).
The standard treatment for IR-PCa is radiation therapy (RT) with or without hormone therapy which can result in cure in some men. In other men, the cancer can come back or spread to other areas of the body. Treatment response in men with IR-PCa is highly variable. This uncertainty has led to significant under- and over-treatment.
Read more
This study aims to find out if the addition of intensive treatment (hormonal therapy: darolutamide + degarelix) to standard treatment for PCa will work better than standard treatment alone. To do this, some participants will receive hormone therapy and others will not. All participants will receive RT.
Currently, it is difficult to identify men who may require more intensive therapy. Current methods, such as using prostate specific antigen (PSA) alone, may not give the doctor enough information about who requires more intensive treatment. The researchers conducting this study believe that a particular arrangement of cancer cells [called intraductal carcinoma (IDC)] and the presence of a genetic marker called SChLAP1 can be used to identify people who would benefit from more intensive therapy.
Hormonal therapy such as with drugs called darolutamide (new drug for PCa) and Degarelix, reduce androgens (male hormones, such as testosterone) or block their effect on the cells. PCa cells require androgens to grow and divide, so removal of androgens may be effective in preventing the return of cancer following radiation therapy.
Although darolutamide has been studied in about 1000 men with PCa and seems promising and well tolerated it is considered an experimental drug, therefore it can only be used in a research study such as this one. Degarelix has been approved by Health Canada to treat PCa.
This is a phase 2, open label, randomized, controlled study and will be conducted across sites in Canada. To qualify, men must have IR-PCa and have both SChLAP1 and IDC present or both absent. Participants will be randomized to receive RT with hormone therapy or RT only. The study treatment period is 6 months for the RT + hormone therapy group. RT will take about 1-2 weeks. All participants will be followed for 5 years with multiple visits to assess safety and treatment effects.
- Conditions
- Prostate Cancer
- Being tested
- Darolutamide, Degarelix, Radiation Therapy
- Keywords
- Intraductal carcinoma, SChLAP1, Radiation therapy
- Medical subject headings
- Prostatic Neoplasms, Carcinoma, Intraductal, Noninfiltrating
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DarolutamideDrug
Also called Nubeqa, ODM-201
Darolutamide will be administered orally as a tablet. Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.
DegarelixDrug
Also called Firmagon
Degarelix is administered by subcutaneous injection. The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.
Radiation TherapyRadiation
The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Radiation Therapy Only | Active comparator | Participants randomized to Group 1 will receive radiation therapy only. Receives: Radiation: Radiation Therapy |
| Group 2: Radiation Therapy + darolutamide + degarelix | Experimental | Participants randomized to Group 2 will receive radiation therapy only + darolutamide + degarelix. Receives: Drug: Darolutamide; Drug: Degarelix; Radiation: Radiation Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recurrence Free Survival
Recurrence Free Survival (RFS), with recurrence event defined as (whichever occurs first):
- Biochemical failure defined as per Phoenix criteria (i.e., a rise in PSA by 2 ng/mL or more above the nadir PSA, confirmed by a second PSA measurement)
- Clinical, radiographic, or pathological evidence of local, regional, or distant recurrence/metastasis
- Initiation of salvage hormonal therapy
- Death from any cause.
Measured: Recurrence Free Survival will be monitored for a duration of 5 years.
Secondary outcomes (8)
Difference in RFS rates (as defined in primary outcome measure) between IDC/SChLAP1 and treatment groups.
To prospectively assess the role of IDC/SChLAP1 in UIR-PCa treated with curative intent radiation to predict those who derive the greatest benefit from ST-2gen-ADT.
Measured: 5 years
Incidence of early biochemical failure as defined by Pheonix criteria (i.e., within first 2 years of follow-up; surrogate of lethal disease).
To determine the impact of ADT hormone therapy combined with radiation therapy compared to radiation therapy alone in improving rates of early failures.
Measured: 5 years
Rates of positive prostate biopsies (local failure) performed at time of recurrence as per standard of care.
To assess the patterns of failure after ST-2gen-ADT combined with SABR compared to SABR alone.
Measured: 5 years
Testosterone levels
To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on the duration of castrate testosterone levels (<50 ng/dL) after treatment completion.
Measured: 5 years
Changes in prostate cancer-specific HRQoL as measured by abbreviated EPIC (urinary, bowel, sexual, and hormonal domains) questionnaire, as a function of treatment assignment
To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on Health Related Quality of Life (HRQOL).
Measured: 5 years
Rate of maximal biochemical control, defined as 2 consecutive undetectable PSA (<0.05 ng/mL) during follow-up.
To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on PSA levels.
Measured: 5 years
Rates of positive molecular imaging results (local, regional and/or distant failure) performed at time of recurrence as per standard of care.
To assess the patterns of failure after ST-2gen-ADT combined with SABR compared to SABR alone.
Measured: 5 years
Changes in prostate cancer-specific HRQoL as measured by SF-12 questionnaire, as a function of treatment assignment
To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on Health Related Quality of Life (HRQOL).
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Nov 2019
- Study start2 Jul 2024 (estimated)
- Primary completionDec 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by University Health Network, TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 208 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Collaborators
- Prostate Cancer Canada, Bayer
- Responsible party
- Sponsor
- Investigators
- Neil Fleshner, MD, Principal investigator, UHN Princess Margaret Cancer CentreAlejandro Berlin, MD, Principal investigator, UHN Princess Margaret Cancer Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04176081
- Sponsor's protocol ID
- SChLAP/IDC Study
- Acronym
- SChLAP/IDC
- Status last verified
- Jan 2024
- First submitted
- 6 Nov 2019
- Last updated
- 24 Jan 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No